Leerink Partnrs Weighs in on STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Stoke Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.49) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at $0.55 EPS.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Stock Up 0.8 %

NASDAQ STOK opened at $8.33 on Friday. The stock has a market capitalization of $441.22 million, a P/E ratio of -3.97 and a beta of 0.99. Stoke Therapeutics has a 52-week low of $5.80 and a 52-week high of $17.58. The firm has a 50-day moving average price of $9.49 and a 200 day moving average price of $11.49.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insider Buying and Selling

In related news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 in the last ninety days. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of STOK. Toronto Dominion Bank acquired a new position in Stoke Therapeutics in the 4th quarter valued at $35,001,000. RTW Investments LP raised its holdings in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after acquiring an additional 471,240 shares during the last quarter. Norges Bank acquired a new position in Stoke Therapeutics in the 4th quarter valued at $3,472,000. Tang Capital Management LLC acquired a new position in Stoke Therapeutics in the 4th quarter valued at $3,309,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Stoke Therapeutics in the 4th quarter valued at $3,218,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.